PHarmaceutical tech@2x
  • News

    Most Read

    • Novartis signs Covid-19 vaccine manufacturing agreement with CureVac
    • Italy blocks export of 250,700 AstraZeneca/Oxford Covid-19 vaccines to Australia
    • Amgen signs agreement to acquire Five Prime Therapeutics for $1.9bn

    Most Recent

    Manufacturing

    Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

    05 Mar 2021
  • Analysis

    Sections

    • Features
    • Comment
    • Projects

    Most Read

    • SIRION and Sanofi partner on next-gen AAV gene therapy vectors
    • Merck-Pandion acquisition: re-balancing immune response to treat autoimmune disease
    • Covid-19 forces working mothers out of the labour force – leading macroeconomic influencers

    Most Recent

    Digital Disruption

    SIRION and Sanofi partner on next-gen AAV gene therapy vectors

    05 Mar 2021
  • Sectors

    Sections

    • Clinical Trials
    • Supply Chain
    • Drug Development
    • Manufacturing
    • Diseases
      • Cardiovascular
      • Central Nervous System
      • Immunology
      • Infectious Diseases
      • Oncology
      • Respiratory

    Most Read

    • COVID-19 Cases Remain Stubbornly High in France and Italy, Possibly Due to UK Variants
    • Novartis signs Covid-19 vaccine manufacturing agreement with CureVac
    • GlobalData Epidemiologist Report: Covid infections climb in central and eastern Europe

    Most Recent

    COVID-19 Cases Remain Stubbornly High in France and Italy, Possibly Due to UK Variants

    05 Mar 2021
  • Themes
  • Deals

    Most Read

    • Amgen signs agreement to acquire Five Prime Therapeutics for $1.9bn
    • SIRION and Sanofi partner on next-gen AAV gene therapy vectors
    • Merck-Pandion acquisition: re-balancing immune response to treat autoimmune disease

    Most Recent

    Oncology

    Amgen signs agreement to acquire Five Prime Therapeutics for $1.9bn

    05 Mar 2021
  • Companies

    Sections

    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos

    Most Read

    • Oncology Therapeutic Development (OTD)
    • LB Bohle
    • Dycem

    Most Recent

    Clinical Trials

    Oncology Therapeutic Development (OTD)

    04 Mar 2021
  • Magazine
  • Events
Menu
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Investment
  • Sectors
    • Clinical Trials
    • Supply Chain
    • Drug Development
    • Manufacturing
    • Diseases
      • Cardiovascular
      • Central Nervous System
      • Immunology
      • Infectious Diseases
      • Oncology
  • Deals
  • Disruption
  • Covid-19 Updates
  • Covid-19 Vaccine Tracker
Partners
  • Accelerating Clinical Trials
  • Powder Handling
  • Simplifying Clinical Trials
Tools
  • Companies
    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos
  • Reports
  • Awards
  • Events
  • Magazine
The Company
  • About Us
  • Contact Us
  • Advertise With Us
  • Visit GlobalData
  • Login
  • Register
  • Login
  • Register
Videos YpsoMate: the two-step autoinjector
Ypsomed
Ypsomed

YpsoMate: the two-step autoinjector

14 November 2014
Share Article
Share Article
Ypsomed
Make an Enquiry

Latest News

Clinical Trials

Atea reports positive Phase I data from oral antiviral agent trial for Covid-19

08 Mar 2021
Manufacturing

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

05 Mar 2021
Regulation

Italy blocks export of 250,700 AstraZeneca/Oxford Covid-19 vaccines to Australia

05 Mar 2021
Oncology

Amgen signs agreement to acquire Five Prime Therapeutics for $1.9bn

05 Mar 2021

Company A-Z

View All

Company Releases

View All

White Papers

View All

Videos

View All
logo-horizontal

Powered by Pharma Tech Logo

  • About Us
  • Editorial Approach
  • Contact Us
  • Terms & Conditions
  • Privacy Policy

© Copyright 2021 Verdict Media Limited.

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more